Reduced platelet glycoprotein Ibα shedding accelerates thrombopoiesis and COX-1 recovery: implications for aspirin dosing regimen.
Paola Simeone, Rossella Liani, Romina Tripaldi, Sonia Ciotti, Antonio Recchiuti, Vittorio Abbonante, Benedetta Porro, Piero Del Boccio, Augusto Di Castelnuovo, Paola Lanuti, Marina Camera, Damiana Pieragostino, Melissa Lee-Sundlov, Myriam Luongo, Raffaella Auciello, Giuseppina Bologna, Maria Concetta Cufaro, Elena Tremoli, Karin M Hoffmeister, Francesco Cipollone, Alessandra Balduini, Francesca Santilli
Author Information
Paola Simeone: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Rossella Liani: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Romina Tripaldi: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Sonia Ciotti: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Antonio Recchiuti: Department of Medical, Oral, and Biotechnological Science, Center for Advanced Studies and Technology (CAST), Chieti.
Vittorio Abbonante: Department of Molecular Medicine, University of Pavia, Pavia, Italy; Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro.
Benedetta Porro: Centro Cardiologico Monzino IRCCS, Milan.
Piero Del Boccio: Department of Pharmacy, Center for Advanced Studies and Technology (CAST), Chieti.
Augusto Di Castelnuovo: Mediterranea Cardiocentro, Napoli.
Paola Lanuti: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Marina Camera: Centro Cardiologico Monzino IRCCS, Milan; Department of Pharmaceutical Sciences, Università degli Studi di Milano, Milan.
Damiana Pieragostino: Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), Chieti.
Melissa Lee-Sundlov: Versiti Translational Glycomics Center and Versiti Blood Research Institute, Milwaukee, WI.
Myriam Luongo: Immunotransfusion Service, Clinical Haematology of Chieti University Hospital.
Raffaella Auciello: Clinical Pathology of Chieti University Hospital.
Giuseppina Bologna: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Maria Concetta Cufaro: Department of Innovative Technologies in Medicine and Dentistry, Center for Advanced Studies and Technology (CAST), Chieti.
Elena Tremoli: Maria Cecilia Hospital, Cotignola.
Karin M Hoffmeister: Versiti Translational Glycomics Center and Versiti Blood Research Institute, Milwaukee, WI, USA; Departments of Biochemistry and Medicine, Medical College of Wisconsin, Milwaukee, WI.
Francesco Cipollone: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti.
Alessandra Balduini: Department of Molecular Medicine, University of Pavia, Pavia.
Francesca Santilli: Department of Medicine and Aging Sciences, Center for Advanced Studies and Technology (CAST), University of Chieti. francesca.santilli@unich.it.
Cardiovascular (CV) disease prevention with low-dose aspirin can be less effective in patients with a faster recovery of platelet (PLT) cyclooxygenase (COX)-1 activity during the 24-hour dosing interval. We previously showed that incomplete suppression of TXA2 over 24 hours can be rescued by a twice daily aspirin regimen. Here we show that reduced PLT glycoprotein (GP)Ibα shedding characterizes patients with accelerated COX-1 recovery and may contribute to higher thrombopoietin (TPO) production and higher rates of newly formed PLT, escaping aspirin inhibition over 24 hours. Two hundred aspirin-treated patients with high CV risk (100 with type 2 diabetes mellitus) were stratified according to the kinetics of PLT COX-1 activity recovery during the 10- to 24-hour dosing interval. Whole proteome analysis showed that PLT from patients with accelerated COX-1 recovery were enriched in proteins involved in cell survival, inhibition of apoptosis and cellular protrusion formation. In agreement, we documented increased plasma TPO, megakaryocyte maturation and proplatelet formation, and conversely increased PLT galactose and reduced caspase 3, phosphatidylserine exposure and ADAM17 activation, translating into diminished GPIbα cleavage and glycocalicin (GC) release. Treatment of HepG2 cells with recombinant GC led to a dose-dependent reduction of TPO mRNA in the liver, suggesting that reduced GPIbα ectodomain shedding may unleash thrombopoiesis. A cluster of clinical markers, including younger age, non-alcoholic fatty liver disease, visceral obesity and higher TPO/GC ratio, predicted with significant accuracy the likelihood of faster COX-1 recovery and suboptimal aspirin response. Circulating TPO/GC ratio, reflecting a dysregulation of PLT lifespan and production, may provide a simple tool to identify patients amenable to more frequent aspirin daily dosing.
References
J Am Coll Cardiol. 2006 Jan 17;47(2):391-7
[PMID: 16412866]
